Stocks like V, HOOD and IBKR are poised to benefit from the next Bitcoin rally.

RL accelerates growth with digital expansion, brand elevation and strong retail performance.

NEWTON, N.C., Feb. 21, 2025 (GLOBE NEWSWIRE) -- The Board of Directors of Peoples Bancorp of North Carolina, Inc., Newton, NC (Nasdaq: PEBK) declared the Company's regular cash dividend for the first quarter of 2025 in the amount of $0.20 per share. The first quarter cash dividend will be paid on March 14, 2025 to shareholders of record on March 3, 2025.

CNBC's Julia Boorstin sits down with InstaCart CEO to discuss how AI will impact grocery shopping.

Kate Rooney sits down with Visa CEO Ryan McInerney to break down the company's investor day, the health of the consumer, and more.

IMAX CEO Rich Gelfond expects $1.2 billion in box office receipts in 2025, fueled by a strong domestic movie slate and improved ticket sales in China. Gelfond pointed to a number of blockbuster titles slated for release in the next 10 months, including a new "Mission Impossible," a live-action "How to Train Your Dragon" film, another "Jurassic Park" installment, a sequel to "Zootopia" and a third "Avatar" release.

LPLA's January brokerage and advisory assets, client cash balance and total net new assets rise on a year-over-year basis.

OLED reports top-line growth year over year, driven by growing traction in the IT, automotive, smartphone and TV end markets.

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your FTAI Aviation Ltd. (NASDAQ:FTAI) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/ftai-aviation-ltd-lawsuit-submission-form?prid=131328&wire=1 or contact Joseph E.

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Pliant Therapeutics, Inc. ("Pliant Therapeutics, Inc.") (NASDAQ:PLRX) concerning possible violations of federal securities laws. On February 7, 2025, Pliant announced that following a prespecified data review and recommendations by the trial's independent Data Safety Monitoring Board, it had voluntarily paused enrollment and dosing in the ongoing BEACON-IPF Phase 2b trial of bexotegrast in patients with idiopathic pulmonary fibrosis.

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Crocs, Inc. (NASDAQ:CROX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/crocs-inc-lawsuit-submission-form?prid=131344&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of CARGO Therapeutics, Inc. ("CARGO Therapeutics, Inc.") (NASDAQ:CRGX) concerning possible violations of federal securities laws. On January 29, 2025, CARGO announced in a press release that it "has elected to discontinue FIRCE-1, a Phase 2 clinical study of firi-cel for patients with large B-cell lymphoma (LBCL) whose disease relapsed or was refractory (R/R) to CD19 CAR T-cell therapy.

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Grocery Outlet Holding Corp. (NASDAQ:GO) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/grocery-outlet-holding-corp-lawsuit-submission-form?prid=131343&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your TransMedics Group, Inc. (NASDAQ:TMDX) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transmedics-group-inc-lawsuit-submission-form-2?prid=131341&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Transocean Ltd. (NYSE:RIG) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/transocean-ltd-lawsuit-submission-form?prid=131345&wire=1 or contact Joseph E.

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your TELUS International (Cda) Inc. (NYSE:TIXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/telus-international-lawsuit-submission-form?prid=131356&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Nextracker Inc. (NASDAQ:NXT) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/nextracker-inc-lawsuit-submission-form?prid=131357&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / If you suffered a loss on your Monolithic Power Systems Inc. (NASDAQ:MPWR) investment and want to learn about a potential recovery under the federal securities laws, follow the link below for more information: https://zlk.com/pslra-1/monolithic-lawsuit-submission-form?prid=131330&wire=1 or contact Joseph E. Levi, Esq.

NEW YORK, NY / ACCESS Newswire / February 21, 2025 / Levi & Korsinsky notifies investors that it has commenced an investigation of Voyager Therapeutics, Inc. ("Voyager Therapeutics, Inc.") (NASDAQ:VYGR) concerning possible violations of federal securities laws. Voyager issued a press release on February 11, 2025, "announc[ing] it has decided to assess alternate payloads related to its gene therapy program for superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS)", stating that "[e]merging preclinical data indicate the siRNA payload component of VY9323 does not meet our high standards due to what appears to be an off-target effect resulting in a narrowed …

CHICAGO , Feb. 21, 2025 /PRNewswire/ -- Kellanova (NYSE: K) today announced that its Board of Directors declared a dividend of $0.57 per share on the common stock of Kellanova, payable on March 14, 2025, to shareowners of record at the close of business on March 3, 2025. The ex-dividend date is March 3, 2025.